Literature DB >> 7070730

Surveillance and management of patients at high genetic risk for ovarian carcinoma.

H T Lynch, W A Albano, J F Lynch, P M Lynch, A Campbell.   

Abstract

The present study is concerned with surveillance/management programs for hereditary ovarian cancer syndromes. These syndromes lack distinguishing premonitory physical signs or biomarkers; therefore, in these genotypic settings, ovarian cancer risk must be assessed by analysis of the patient's pedigree. The authors describe 10 families showing a hereditary proclivity to ovarian carcinoma and/or associated cancer(s) in accord with their respective cancer-prone genotypes. Cancer education, genetic counseling, and surveillance should be instituted early. In addition to bimanual pelvic examination, ultrasound should be tested for its possible efficacy as a screening technique. The option of prophylactic bilateral oophorectomy and hysterectomy is thoroughly discussed with highly selected candidates. The authors believe that the aggressive management approach proposed for ovarian carcinoma is warranted for high-risk members of cancer-prone families, wherein the risk for ovarian cancer may approach 50%.

Entities:  

Mesh:

Year:  1982        PMID: 7070730

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  15 in total

1.  Age at diagnosis and multiple primary cancers of the breast and ovary.

Authors:  P J Suris-Swartz; J M Schildkraut; M F Vine; I Hertz-Picciotto
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Ascertainment of familial ovarian cancer in the Aberdeen Genetic Clinic.

Authors:  H Gregory; A Schofield; D de Silva; J Semper; B Milner; L Allan; N Haites
Journal:  J Med Genet       Date:  1996-03       Impact factor: 6.318

3.  D-14 monoclonal antibody to carcinoembryonic antigen: immunohistochemical analysis of formalin-fixed, paraffin-embedded human colorectal carcinoma, tumors of non-colorectal origin and normal tissues.

Authors:  Z P Pavelic; N J Petrelli; L Herrera; M M Vaughan; J S Paecock; L Pavelic
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 4.  Genomic Biomarkers for Breast Cancer Risk.

Authors:  Michael F Walsh; Katherine L Nathanson; Fergus J Couch; Kenneth Offit
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

5.  Evaluation of microRNA expression profiles and their associations with risk alleles in lymphoblastoid cell lines of familial ovarian cancer.

Authors:  Jie Shen; Dan Wang; Steven R Gregory; Leonard Medico; Qiang Hu; Li Yan; Kunle Odunsi; Shashikant B Lele; Christine B Ambrosone; Song Liu; Hua Zhao
Journal:  Carcinogenesis       Date:  2012-01-10       Impact factor: 4.944

6.  Novel genetic variants in miR-191 gene and familial ovarian cancer.

Authors:  Jie Shen; Richard DiCioccio; Kunle Odunsi; Shashikant B Lele; Hua Zhao
Journal:  BMC Cancer       Date:  2010-02-18       Impact factor: 4.430

7.  Family history in ovarian cancer referral population.

Authors:  L A Berg; S Robert Young; K A Brooks; A M Davis; S Terry Smith
Journal:  J Genet Couns       Date:  1996-03       Impact factor: 2.537

8.  Recognition and treatment of patients with hereditary nonpolyposis colon cancer (Lynch syndromes I and II).

Authors:  R J Fitzgibbons; H T Lynch; G V Stanislav; P A Watson; S J Lanspa; J N Marcus; T Smyrk; M D Kriegler; J F Lynch
Journal:  Ann Surg       Date:  1987-09       Impact factor: 12.969

9.  Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer.

Authors:  H Tulinius; V Egilsson; G H Olafsdóttir; H Sigvaldason
Journal:  BMJ       Date:  1992-10-10

10.  Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship.

Authors:  J M Schildkraut; N Risch; W D Thompson
Journal:  Am J Hum Genet       Date:  1989-10       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.